Dr. Slomovitz on the Key Objectives of the KEYNOTE-B21 Trial in High-Risk Endometrial Cancer

Brian M. Slomovitz, discusses the phase 3 ENGOT-en11/GOG-3053/KEYNOTE-B21 trial.

Brian M. Slomovitz, MD, co-chair, Cancer Research Committee, director, Gynecologic Oncology, Mount Sinai Medical Center Miami Beach; clinical trial advisor, member, Board of Directors, the GOG Foundation; professor, Obstetrics and Gynecology, Florida International University, discusses the phase 3 ENGOT-en11/GOG-3053/KEYNOTE-B21 trial (NCT04634877).

The trial in progress is evaluating pembrolizumab vs placebo in combination with adjuvant chemotherapy with or without radiation therapy in patients with newly diagnosed high-risk endometrial cancer after surgery with curative intent, Slomovitz says. This trial is unique in that it allows for the administration of radiation therapy based on clinician discretion, Slomovitz adds. Adjuvant trials in endometrial cancer have proven to be difficult to get started, according to Slomovitz, who adds that KEYNOTE-B21 seeks to enroll 990 patients.

The purpose of the large, global trial is to understand whether the addition of pembrolizumab will improve outcomes in patients with high-risk endometrial cancer, Slomovitz adds. It is known that immunotherapy is effective in those with recurrent disease and for those with microsatellite instability, immunotherapy in the single-agent setting would be indicated, Slomovitz concludes. 

Related Videos
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Alastair Thompson, BSc, MBChB, MD, FRCS
C. Ola Landgren, MD, PhD
Sara M. Tolaney, MD, MPH
Adam M. Brufsky, MD, PhD, FACP
Justin M. Watts, MD
Sara M. Tolaney, MD, MPH
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine